Blogs
Anthony (Tony) Fauci will step down this month as chief medical advisor to US President Joe Biden and as director of the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health. I interviewed Fauci for an editorial we published today that reflects on the lessons he has learned throughout his long career in public service. A lightly edited transcript of
I wrote here about the measurement of electric fields inside enzyme active sites, and now the same group has published two more papers in this area. Both of them focus on beta-lactam compounds as a test case.
This paper is looking at covalent inhibitors of beta-lactamase enzymes, which are very important compounds. A classic one, clavulanic acid, is part of the Augmentin drug combination (which ha
Update: Moderna contacted me about this post, and they have the following on-the-record statement about this trial and its statistics:
The primary efficacy endpoint and statistical plan of KEYNOTE-942 were pre-specified in the protocol. The trial was powered from the start to demonstrate 1-sided superiority of mRNA-4157/V940 plus KEYTRUDA versus KEYTRUDA monotherapy. Signal seeking trials are
Editor's Blog
Anthony (Tony) Fauci will step down this month as chief medical advisor to US President Joe Biden and as director of the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health. I interviewed Fauci for an editorial we published today that reflects on the lessons he has learned throughout his long career in public service. A lightly edited transcript of
An accomplished actor best known for his portrayal of Captain Benjamin “Hawkeye” Pierce in the US television series M*A*S*H, Alan Alda has taken on another impactful role in recent years: champion of science communication. Having served for 14 years as the host of Scientific American Frontiers, a public television show devoted to explaining recent advances in science and technology, in
Royce W. Murray, a pioneer in electrochemistry, chemically modified electrodes, self-assembled monolayers, and ionic liquids, died on 6 July at age 85. Much of how we think about modifying surfaces and measuring changes induced by those modifications comes from Murray’s lab. Murray’s scientific accomplishments have been enumerated elsewhere, but those who knew him will best remember hi
Ten years ago, an editorial in Science remarked on how little progress had been made on improving the postdoctoral experience since a landmark report in 2000 detailed the variability of such positions. Postdoctoral scholars (postdocs) are hardly better off in 2022; however, postdoctoral fellowship programs can serve as the nuclei for changes that have long been recognized as necessary for improvin
The past 2 years have been a period of mourning, anger, fear, and exhaustion for Asian Americans: 16% of Asian American adults were victims of hate crimes in 2021, up from 12.5% in 2020; 31% worry “all the time” or “often” about being victimized because of their race; and 36% have changed their routines over concerns about personal safety. Despite the increase in anti-Asian
Our food system is a rich, complex blend of biology and culture. From the biodiversity in forests, oceans, and farms to the living weave of long-standing traditions and emerging trends, food touches every aspect of life on Earth. This diversity hasn’t always carried through to agricultural and culinary literatures, but fortunately this is changing. Fresh perspectives are emerging in the lite
Advertisement
Advertisement
Visuals
Have you ever wondered why some research makes science news and other research doesn’t? Of course, content is king but in addition to having significant findings, strong visuals can catch the attention of the press and larger audiences. It pays to spend some time taking high-quality photos of your work and putting them somewhere a photo editor (a person like me that seeks out pictures for news sto
I remember first learning about the nuclear pore. It was in high school biology, and I was immediately struck by how it looked. Its symmetry certainly stands out: eight copies of a protein unit arranged in a ring, encircling an opening in the nuclear membrane. And they cover the nucleus like holes in a colander (if that colander was very choosy about what it let through). The next thing one notice
Working with animals is unpredictable by nature. To them, there are always more interesting things to be doing, fresh smells to sniff, and new acquaintances to make. After reading the paper on dog breed stereotypes for the 29 April issue of Science, I knew we had to have a cover with as many dogs as possible. But if you’ve ever walked by a doggy daycare, you know it’s nearly impossible to get a group of dogs to focus on one thing, let alone sit still for a portrait.
I was fascinated by the complex shape of the intricate glass sculpture. Yet it was only 4.5 millimeters tall—less than the thickness of a No. 2 pencil. But the small scale posed a big problem: Would a photograph of such a minute object work as a Science cover?
In the Pipeline
I wrote here about the measurement of electric fields inside enzyme active sites, and now the same group has published two more papers in this area. Both of them focus on beta-lactam compounds as a test case.
This paper is looking at covalent inhibitors of beta-lactamase enzymes, which are very important compounds. A classic one, clavulanic acid, is part of the Augmentin drug combination (which ha
Update: Moderna contacted me about this post, and they have the following on-the-record statement about this trial and its statistics:
The primary efficacy endpoint and statistical plan of KEYNOTE-942 were pre-specified in the protocol. The trial was powered from the start to demonstrate 1-sided superiority of mRNA-4157/V940 plus KEYTRUDA versus KEYTRUDA monotherapy. Signal seeking trials are
There have been plenty of posts about targeted protein degraders around here the last few years, and it’s a safe bet that there will be plenty more. And at the same time, there are many other weird and interesting therapeutic ideas coming on that depend on the same sorts of large, “undruglike” molecules that you see with the bifunctional TPD ones. What’s interesting is that many of these thin
I’ve been meaning to blog about this recent advance in mRNA vaccines, a new multivalent candidate with the widest range ever tried against influenza. It’s worth a look to see how this was done, and what it might mean (or might not) as it goes forward.
Flu is a tough vaccination problem, as is well known. Everyone’s heard of the years when the seasonal vaccine turns out to be a po
One of the simplest ways to classify proteins is into bins called “folded” and “unfolded”, and many of us slide into that shorthand when describing them. But it’s too simple. There are proteins that adopt a consistent three-dimensional structure that is nonetheless wrong, which are better categorized as “misfolded”, and there are proteins that have distinc
I wrote here recently about lecanemab, the latest anti-amyloid antibody being tested as an Alzheimer’s therapy. But there’s another aspect to this drug (and apparently to the other attempts at such antibodies) that hasn’t had as much attention. Madhav Thambisetty, a neurologist at the National Institute on Aging, has an opinion piece at Stat where he lays it out: the Phase II tri











